Skip to Content

Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCURO1450


PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

Principal Investigator(s)

David Penson


  • Protocol No. VICCURO1450
  • Open Date: 08/13/2014
  • Staging: Phase III
  • Age Group: Adults
  • Scope: International
  • Objective: To determine the efficacy of enzalutamide compared with placebo as assessed by metastasis-free survival (MFS).
  • Disease Sites: Prostate
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Enzalutamide; MDV3100
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT02003924
  • Secondary Protocol No: MDV3100-14


None Provided.


Not provided. Please call for more information.